Cingulate(CING) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update Industry Veteran Bryan Downey Named Chief Commercial Of icer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ...